KBC Group
MDCO

KBC Group’s Medicines Co MDCO Stock Holding History

KBC Group’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-22,410
Closed -$1.9M – 1519
2019
Q4 		$1.9M Hold
22,410
– – 0.01% 698
2019
Q3 		$1.12M Hold
22,410
– – 0.01% 830
2019
Q2 		$817K Hold
22,410
– – 0.01% 915
2019
Q1 		$626K Buy
+22,410
New +$528K 0.01% 1018
2018
Q1 		– Sell
-51,830
Closed -$1.42M – 1332
2017
Q4 		$1.42M Sell
51,830
-97,269
-65% -$3M 0.01% 689
2017
Q3 		$5.52M Buy
149,099
+2,347
+2% +$86.5K 0.05% 375
2017
Q2 		$5.58M Buy
146,752
+7,377
+5% +$329K 0.05% 346
2017
Q1 		$6.82M Buy
139,375
+52,837
+61% +$2.41M 0.06% 336
2016
Q4 		$2.94M Buy
86,538
+5,156
+6% +$183K 0.03% 535
2016
Q3 		$3.07M Buy
+81,382
New +$3.07M 0.04% 461

Other funds holding MDCO

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

KBC Group's MDCO Position: Q1 2020 in Review

KBC Group sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 22,410 shares — an estimated $1.9M sold.

KBC Group first reported a position in MDCO in Q3 2016 and held it in 10 quarters. The position peaked at $6.82M in Q1 2017. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

  • KBC Group reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
  • KBC Group sold 22,410 Medicines Co shares in Q1 2020, an estimated $1.9M.
  • KBC Group first reported a position in Medicines Co in Q3 2016 and held it in 10 quarters.
  • KBC Group's Medicines Co position peaked at $6.82M in Q1 2017.
  • 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on KBC Group's 13F filing for Q1 2020, filed 4 May 2020.